Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
sell no more then 30% of this company ever if you plan on a buy back for a lower price...thats my take..
remember my opinions so have your own.
Every company dealing in primarily stem cell related therapies had a roughly 10-15% increase today... And I mean everyone, across the board practically. Meaning there is something going on behind the scene likely political origin regards to the fda announcing approval of a stem cell based therapy (finger crossed actc) or through channels it has been made clear but not yet released. Or even a recent discovery which has explosive anD immeasurable potential for profit within the field. or the final reason behind this could be...FUNDING!! dun dun DUUUUUN!
Something big has happened ladies and gents... W/E it is it is GOOOOOD NEWS FOR US ALL!
Its very very likely with this kinda movement across the board.
damnit.. I wanted to buy 100k more shares to add to my portfolio while it remained at those levels... a buy at .085 or .08 would have been amazing
hERE IS THE TRANSLATED VERSION OFF EBIOTRADE AGAIN
I would recommend to you all that you bookmark the site and pick up the firefox add-on translator... it is the best online translator that I have ever used.. and if needed I think it sends the text to a person to translate if the machine can not.
but here is the text of the information
"Picture in Picture PIP ads ads start the end of Abstract: founded just two years, "Cell Stem Cell", a washed impact factor from 0 to 16.826, stem cell research has become the authoritative journal in December coming to an end, "Cell Stem Cell "summed up what most attention in December of the first 20 articles. Domestic scholars, Professor Pei-ching iPS-side research, published in the online edition of Cell Stem Cell just over one weeks time on December ranked the most talked about top 20 articles. Science Daily, founded just two years, "Cell Stem Cell", a washed impact factor from 0 to 16.826, stem cell research has become the authoritative journal in December coming to an end, "Cell Stem Cell" summed up a bit in December of the most concern the first 20 articles. 2009 Top Ten Technology Person of the Year Award, please vote! It is worth mentioning that, many Chinese scholars, Professor Pei-ching of the iPS-side research, published in the online edition of Cell Stem Cell just over one weeks time on December ranked the most talked about top 20 articles. From the "Cell Stem Cell" the most talked about article 20 information can be seen that the current iPS is still popular in the popular, in December many articles iPS research papers into the top 20 downloads in the list. The first Vitamin C Enhances the Generation of Mouse and Human Induced Pluripotent Stem CellsMiguel Angel Esteban, Tao Wang, Baoming Qin, Jiayin Yang, Dajiang Qin, Jinglei Cai, Wen Li, Zhihui Weng, Jiekai Chen, Su Ni et al. IPS for improving the conversion efficiency of the mainstream of the international stem cell research focused on the regulation of factors within the nucleus and high-throughput small molecule screening, the Pei-ching-side team of researchers led by experimental research directions will be placed in the extracellular environment - culture medium composition. In the study of somatic cell reprogramming process, they found that changes in cellular energy metabolism occurred in the time will produce large amounts of reactive oxygen species (ROS) components, these components can lead to cell aging may be caused by induced pluripotent stem cells into the reasons for low efficiency . This phenomenon prompted the research team generated in the medium where adding anti-oxidants to improve the efficiency of somatic cell reprogramming the idea, after a series of experiments, they found that vitamin C's role in this magic. Vitamin C, found in over 250 years of history that, with its antioxidant characteristics and the importance of tissue repair is known, this research shows vitamin C is just to slow down the cell aging to some extent, evidence of vitamin C The health significance, but also to improve the efficiency of iPS generation to develop a simple method, and the basic mechanism of re-programming has been a further understanding of stem cell research opens a new direction. The second Technical Challenges in Using Human Induced Pluripotent Stem Cells to Model Disease Krishanu Saha, Rudolf Jaenisch seventh A Small-Molecule Inhibitor of Tgf-ß Signaling Replaces Sox2 in Reprogramming by Inducing Nanog Justin K. Ichida, Joel Blanchard, Kelvin Lam, Esther Y. Son, Julia E. Chung, Dieter Egli, Kyle M. Loh, Ava C. Carter , Francesco P. Di Giorgio, Kathryn Koszka et al. ninth Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins Hongyan Zhou, Shili Wu, Jin Young Joo, Saiyong Zhu, Dong Wook Han, Tongxiang Lin, Sunia Trauger, Geoffery Bien, Susan Yao, Yong Zhu et al. from the Scripps Research Institute (Scripps Research Institute) Dr. Ding Sheng of the recombinant protein can induce pluripotent stem cells, the move is undoubtedly a great breakthrough in the field of stem cells. The biggest challenge they face is how to make four proteins penetrate the cell membrane into the cell. Ding Sheng, who has completed the in vitro and in vivo experiments in mice, after 4 protein in cells induced pluripotent complete. These iPS cells into mouse embryos to form chimeric mice, after inspection, there are two kinds of mice in vivo cell lines of different genetic backgrounds, which confirmed the induced pluripotent embryonic cells. Ding Sheng said that the current efficiency of this technology is not viral vector-induced high efficiency, they will continue to verify the technology of human cells. 13th Name Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins Dohoon Kim, Chun-Hyung Kim, Jung-Il Moon, Young-Gie Chung, Mi-Yoon Chang, Baek-Soo Han, Sanghyeok Ko, Eungi Yang , Kwang Yul Cha, Robert Lanza et al. Stem Cell Research Center at Harvard Medical School scientists have also developed this new recombinant protein induced by technology, and taken the lead in bringing this technology to the human body human fibroblast cells. Stem Cell Research Center at Harvard University researchers have won a victory for the first time succeeded in human fibroblasts induced by the four recombinant proteins into iPS cells. IPS-induced recombinant protein constitutes the main component of technology are: 4 recombinant protein (Oct4, Sox2, Klf4 and c-Myc) and the promotion of the recombinant protein peptides to penetrate cells (cell-penetrating peptide, CCP). In the CCP's help, the recombinant protein into fibroblasts, promoting cells into iPS cells. Articles Corresponding Author, stem cell and regenerative medicine, said Robert Lanza, chief scientist, this is a safe iPS technology, they will as soon as possible to upgrade from basic research into the cell therapy research. They hope next year to bring this technology to clinical trials. At present, compared with other iPS technology, recombinant protein-induced iPS is a health risk to the lowest technology. Despite the current induced by the efficiency of this technology is relatively low, Lanza said that they would purified recombinant protein in order to enhance the efficiency of protein delivery, thereby increasing the efficiency of iPS induction. (Bio-Link Amanda) (http://www.ebiotrade.com/) All rights reserved without written permission shall not be reproduced "
Basically it discusses how act is planning on entering clinical trials for another technology this year as well.
I meant to translate this sorry
http://www.ebiotrade.com/newsf/2009-12/20091231171605776.htm
I'll post a very detailed reference to all your needs for a greater understanding of the IND process and requirements and you can better understand it for yourselves and ascertain your own opinions
http://www.access.gpo.gov/nara/cfr/waisidx_03/21cfr312_03.html
Its extensive and might be difficult for some of you to read or fully understand but it is there if you need it
This might be a good source for some
http://edocket.access.gpo.gov/cfr_2003/aprqtr/pdf/21cfr312.20.pdf
"Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, FDA has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk."
what this very well can mean is that after the 30 period is over unless they announce a hold clinical trials they can begin immediately... which I believe is what has happened
Understand the process have already begun.. the fda did not give a halt order and from what I've read after 30 days if a halt order was not given they are free to proceed.
Look into the fda process for clinical trials and you will understand.. unless I'm mistaken which i do not believe I am.
remember these are all my opinions based on my research to be a safe investor do your own research and make your own decision
Please read to understand.
There are waiting to release several posts at once... trying to muster interviews and reports to create a boom effect...I am sure that they have set up several interviews with papers and publication and talk shows for lanza to visit... and then likely in the middle of all this they release the approval and the beginning to curing blindness... its a very strong move
they effect that will have will bolster pps over a span of time so that the company finds several solid long term investors instead of shorters... they are trying to create stability in pps so they are going to persue an advertising initiative on the legs of the fda approval and the new political climate.
since the lifting of the ban there has been some focus yet most news outlets are still clamoring for something to right since it is still young and many companies do not yet have anything to announce.. most of the companies are just starting to be created.
when they do announce it they will do it behind a strong surge in interviews and publicity
they will gain strong long term investors and limit the short term pumpers.. making the pps strong and be able to create stability in the pps
its a good tactic. If we do see bad numbers in January for the economy as a whole and experience panic or a strong dip, then delaying the release of information is even a stronger move... people will be looking for a place to go ... all around it is a very strong move just to wait and plan the release of this information
my research and my opinions do your own please before making any moves.
New article in bloomberg
We're starting to get more and more attention
http://www.bloomberg.com/apps/news?pid=20601124&sid=axgmWSy1i6vU
HBO series on cloning, actc potentially written into script?
There is a good possibility that actc is written into the script seeing as how it was written about cloning which actc pioneered and right around the time dolly the sheep was cloned at actc.
this could be GREAT GREAT publicity if it does happen.. millions of people will hear the name advanced cell technology, not to mention in the second quarter will will most likely hear about FDA approval... the butterfly effect could really be something else.
http://www.broadwayworld.com/article/HBO_Films_Premieres_Caryl_Churchills_A_Number_1229_20091228
New article
http://www.telegram.com/article/20091227/NEWS/912270400/1003/NEWS03
Nothing special, but I list every release
Its rather evident that they are proceeding with the clinical trials however formal approval will come in the 2nd Q in my opinion.
The FDA in likely to demand more information at times but the scientific team at actc is composed of the most renowned scientist in the field of cell therapy. With that said, its more likely then any other company to proceed without interruption on intellectual property.
The company has also stated that it has sufficient capitol to go into 2011, well into it. It is further my contention that with the coming of the second quarter we will see astonishing results fallowing the FDA approval and share value will surge.
The most pressing concerns seem to be dilution, management, and retention of intellectual property. Potential suits filed to protect property and patents is also an issue. Not to mention theft of research by any of the large and and substantially capitalized companies and organizations who are in collaboration with actc on any number of projects.
I believe that further capitalization coming in the second quarter would SUBSTANTIALLY improve its situation in regards to property, research, and share value.
This being said there is also a reasonable possibility that we will experience a double dip recession fallowing the holiday numbers and the butterfly effect it may have had on the economy as a whole. If that happens to be the case we will need to see where investors will go with their capitol, and what portion of the market will remain invested, liquidated, and or poured into commodities such as gold and precious metals. The potential for fire sale prices due to liquidation and a turn to gold and other precious metals is strong if we do experience a double dip recession. Sell offs will likely be stronger then ever and could lead into depression if not careful.
one way that actc could benefit is in its timing, uncharted potential, and room for growth of invested. a great number of investors will likely be looking to re-enter the market around the 2nd Q if a large scale liquidation does occur. ACT will be perfectly positioned with its FDA approval and its recession proof potential medicine/treatments to muster a large scale drive by investors to pick up and own shares while they are cheap.
However the problems are still there and its hard to tell how investors will reacted to the current dilution and risks that are present with any new and emerging technology.
Most of us here KNOW in the current political climate ACT will most definitely succeed and advance a great deal, but to what level is uncertain seeing as how several other new US stem cell therapy firms have been created and they are all well capitalized for R&D and the patents that could very well result from them.
The mission goal for act is a difficult one because its first steps are designed to bring them up to the level of other better capitalized biotech firms. And once RPE is a success they still have to market it but no need to explain there.
After a reasonable measure of capitalization is reached they will then resume the real goal.. patent creation and retention which they are better suited for then any other firm in regards to intellectual talent and that is really what it boils down too, intellectual genuis to create what others could not and we have the best of it.
It is the reason why I have retained a great deal of shares. The effects of being able to deny company licenses to specific patents so that your own company can create technology resulting from it is and unmeasurable advantage.
Its a race and unfortunately we are now behind due to that hillbillay president bush who brought religion into government... all other countries advanced with the science regarding cell therapy while we remained at a relative stand still... but thats changed.
However, I should remind you all these are all merely my opinions, you should formulated your own through extensive research and extensive thought on the matter.
GLTUA and happy holidays
There is immense potential
My question is why I was the only one able to find this through research and why no information as been released stateside.... although the recent influx of shares bought might be a hint as to how there are others who are better informed
how did she come to learn of it?
there is the link if u can translate but it seems that it already has been done by the person below
http://www.ebiotrade.com/newsf/2009-12/20091217172539462.htm
Also read the bio Europe report... it seems that they say they expect to begin clinical trials Q1 of 2010 and get FDA approval Q2 2010.. so I think there was some problems with the translation...
Wheres someone who speaks Chinese when you need them.
I think whats happened is they meant that they have the go ahead to start clinical trials since the 30 day grace period of review is over and the FDA did not issue a halt order... the actual official approval will come in the second quarter? I dunno, all I know is what I read on that article via translation.... but I believe they do have the go ahead to begin clinical trials since a halt order has not been issued by the FDA after the 30 day period after the submission...
But I could be wrong.. wish there was a better way to translate material over the web... would make obtaining information all the more merrier
Does anyone speak chinese so they can give a proper translation to the article I posted
oh you can read chinese... then here is the exact article... you tell me what it said
http://www.ebiotrade.com/newsf/2009-12/20091217172539462.htm
thats cool.. but its kinda random... has he ever ruled over and cases anyone would know about?
no I don't... I sold a large portion a while ago
part of me regrets telling everyone here and on google so soon... i forgot about a couple people i wanted to tell first...but i've been spreading the info around fast... now im trying to get rid of it lol
i got over excited
my god father is a commodity trader and I wanted to let him know before I told everyone else but I got caught up in the excitement a spilled the beans... but no news outlets seem to have picked up on it state side.. so if it does prove accurate and he gets my mails and text I guess he still has time to make a decision
the last post in short said that clinical trials were approved by the fda.. but it hasn't been made public in the american media outlets.. my gift to you all at investor hub...its based off a translation... do what you will with the information
Article on clinical trail being approve. Chinese site called biotrade.com
Abstract: Science Daily, "Science" magazine launched in 2009 breaking the occasion of the annual top ten are also a hot topic of science in 2010 were predicted, including stem cells, pluripotent stem cells to treat neurological diseases have been considered in the coming year will be a hot topic. Please follow the bio-pass editor recalled in 2009 the development track of the various stem cells to explore the stem cells next year to continue popular causes. Science Daily, "Science" magazine launched in 2009 breaking the occasion of the annual top ten are also a hot topic of science in 2010 were predicted, including stem cells, pluripotent stem cells to treat neurological diseases have been considered in the coming year will be a hot topic. Please follow the bio-pass editor recalled in 2009 the development track of the various stem cells to explore the stem cells next year to continue popular causes. 2009 Life Science Top Ten selection of innovative products, please vote! The topic of stem cells in 2009 is absolutely hot, as in March this year, Obama gave an order to lift the ban on embryonic stem cell research, the U.S. life sciences term, scientists are eagerly preparing themselves to the full field of embryonic stem cells. Followed popular, in 2009, the U.S. FDA approved two cases of clinical trials of embryonic stem cells, albeit the first clinical trials of embryonic stem cells since suffered a bottleneck, but the second from the recent clinical trials of embryonic stem cells was approved and is being carried out in full swing . The first clinical trials of embryonic stem cells, January 23, 2009, Geron announced, FDA has approved to carry out the world's first human embryonic stem cell therapy in clinical trials. Geron Corporation announced that it would then 8-10 with spinal injuries leading to paraplegia in patients with injections GRNOPC1. If successful, will conduct the clinical Phase III trial in the summer. Geron's human embryonic stem cell products: GRNOPC1, a kind of nervous tissue from progenitor cells injected into the spinal cord is used to treat neurodegenerative diseases. Currently, Geron's clinical trial was not carried out, not knowing what the reason for FDA continues to collect data on Geron's animal experiments. A similar thing is occurring not only in the Geron Corporation, in February of this year, but also a disruption of neural stem cells in clinical trials. This is the FDA the results of a precaution, after all, too many unknown risks, only to have more evidence to go about carrying out human trials. The second clinical trial of embryonic stem cells November 18, Advanced Cell Technology (ACT) submitted to the FDA a human embryonic stem cells and application for phase II clinical trials. This is the second world's first cases of human embryonic stem cells, clinical trials, blocked, the world's second case of human embryonic stem cells, clinical trials, recently approved by the U.S. FDA has formally launched a clinical trial. ACT's embryonic stem cell clinical trial project is aimed at hereditary eye disease. New Jersey project participants of the Macro Zarbin University School of Medicine, said the project I am cautious but optimistic. Compared with other experiments, the stem cells in the retina is relatively more likely to play a role. Robert Lanza, chief scientist, according to ACT introduction, a previous animal experiments showed that using embryonic stem cells to treat Stargardt disease (a hereditary eye disease) are very effective, and there were no toxic side effects. This allows us to believe that human trials will be successful. Poland, Casey Eye Institute will also participate in the clinical trials, the hospital, said Peter Francis, from the preliminary data from animal experiments to get a great deal of confidence that FDA has accepted our application in the information on next year approval of our clinical trials carried out for six months. Bio-Link Comment: stem cells, regenerative medicine, these words in the next few years will become the most popular topic, but it allows people excited is finally out of the theoretical research laboratories, the clinical path of the. The significance of access to clinical trials, stem cell therapy closer to reality. No matter what difficulties the road, I believe that scientists will continue to move forward. (Biological Tong Zhang Huan) (http://www.ebiotrade.com/) All rights reserved without written permission shall not be reproduced
Merry Christmas and good luck everyone
Can you please verify that with the article.
1M as in 1,000,000
I might just sell 1 M shares today keeping half just in case... but I'm still thinking it through because of the up and coming news that I believe will come in july and august. I see mid July to early September being a rocket type atmosphere for this stock so I'm a little worried about selling today to be side winded with a small press release that could sustain it at a higher level until the weekend. Trading this stock after july will be very high risk unless you don't mind missing a huge premarket gain fallowed by a rally. I'm going to make my mind up on the matter around 1-3 depending on its movement and levels... thats going to be the key indicator of the day on whether it will finish with a peak or a drop...Very risky decision I have to make here, Alot of money. Any thoughts?